Status:
RECRUITING
Monotherapy of an NMDA Enhancer for Schizophrenia
Lead Sponsor:
China Medical University Hospital
Collaborating Sponsors:
National Health Research Institutes, Taiwan
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Previous studies found that some NMDA-enhancing agent was able to augment antioxidant activity and its adjunctive therapy was better than placebo in reducing clinical symptoms and cognitive deficits a...
Detailed Description
Several lines of evidence suggest that schizophrenia is associated with accelerated aging and oxidative stress may play a role. Cognitive deficits are core symptoms of accelerated aging in patients wi...
Eligibility Criteria
Inclusion
- Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia
- Refuse or are unable to tolerate antipsychotics due to poor response or adverse effects
- PANSS total score ≥ 60
- Free of antipsychotic drugs for at least 1 week
- Agree to participate in the study and provide informed consent
Exclusion
- Current substance abuse or history of substance dependence in the past 3 months
- History of epilepsy, head trauma, stroke or other serious medical or neurological illness which may interfere with the study
- Use of depot antipsychotic in the past 3 months;
- Clinically significant laboratory screening tests
- Pregnancy or lactation
- Inability to follow protocol
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04745143
Start Date
January 1 2018
End Date
December 1 2025
Last Update
August 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan